Cognition Therapeutics Announces Public Offering

Cognition Therapeutics, a company focused on treating neurodegenerative disorders, has priced a public offering of common stock at $1.75 per share. The offering is expected to raise approximately $11.5 million, with the option for additional shares. The company plans to use the proceeds for research, development, and general corporate purposes. Titan Partners Group is managing the offering, which is expected to close on March 14, 2024. Cognition Therapeutics is known for its innovative approach to targeting degenerative diseases of the central nervous system and retina. The company's lead candidate, CT1812, is being studied in clinical programs for Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration. Cognition believes that CT1812 can regulate pathways impaired in these diseases by targeting the σ-2 receptor, offering a unique approach compared to other treatments in development. Forward-looking statements in the press release caution investors about potential risks and uncertainties associated with the offering. For more information about Cognition Therapeutics and its pipeline, visit https://cogrx.com.